InvestorsHub Logo
Followers 3
Posts 283
Boards Moderated 0
Alias Born 06/06/2014

Re: None

Monday, 10/02/2017 7:55:08 AM

Monday, October 02, 2017 7:55:08 AM

Post# of 12450
Q 4 actions that are expected according to company statements.

Rizaport file with FDA in Oct.

Manufacturing facility anticipated approval from Health Canada.

Expert opinion on Tadalifil expected.

Tadalifil filed in Q4.

Parter for Tadalifil announced JMHO near the date of Lilly patent expiry.

Partner for rizaport in Q4 JMHO.

Update on Montelukest study for Phase 2 trials.

All above based on company published statements.

Can't post on Yahoo conversations board Network error?? Anyone know how to fix?

RRM
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent IGXT News